Rafferty Asset Management LLC Sells 3,040 Shares of Krystal Biotech, Inc. $KRYS

Key Points

• Rafferty Asset Management LLC reduced its stake in Krystal Biotech by 11.2%, selling 3,040 shares during the first quarter, now owning approximately 24,161 shares valued at $4.36 million.
• Several institutions including Brooklyn Investment Group and Fifth Third Bancorp made significant increases to their holdings in Krystal Biotech during the same quarter.
• Krystal Biotech reported a $1.29 EPS for the quarter, exceeding analyst estimates, and has an average analyst rating of "Buy" with a price target around $210.38.

Rafferty Asset Management LLC lessened its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 11.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,161 shares of the company's stock after selling 3,040 shares during the quarter. Rafferty Asset Management LLC owned approximately 0.08% of Krystal Biotech worth $4,356,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of KRYS. Brooklyn Investment Group increased its stake in shares of Krystal Biotech by 291.7% during the 1st quarter. Brooklyn Investment Group now owns 141 shares of the company's stock worth $25,000 after purchasing an additional 105 shares during the last quarter. Fifth Third Bancorp increased its stake in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after purchasing an additional 105 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Krystal Biotech by 128.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 315 shares of the company's stock worth $58,000 after purchasing an additional 177 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Krystal Biotech during the 1st quarter worth $74,000. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Krystal Biotech during the 4th quarter worth $95,000. Institutional investors and hedge funds own 86.29% of the company's stock.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the completion of the transaction, the insider directly owned 1,443,276 shares of the company's stock, valued at $216,924,382.80. This trade represents a 0.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders have sold 49,800 shares of company stock worth $7,487,943. Company insiders own 13.70% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Guggenheim lowered their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research note on Friday, August 22nd. Citigroup reiterated a "neutral" rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Bank of America lowered their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Finally, Chardan Capital lowered their target price on shares of Krystal Biotech from $219.00 to $216.00 and set a "buy" rating on the stock in a research note on Friday, August 22nd. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Krystal Biotech has an average rating of "Moderate Buy" and a consensus target price of $210.38.

Krystal Biotech Stock Down 2.0%

NASDAQ KRYS traded down $3.06 during midday trading on Friday, hitting $147.70. The company had a trading volume of 257,853 shares, compared to its average volume of 393,550. The stock has a market cap of $4.27 billion, a price-to-earnings ratio of 30.02 and a beta of 0.66. The firm has a fifty day simple moving average of $145.83 and a two-hundred day simple moving average of $154.31. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.21. The company had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. As a group, equities analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).